Accordingly, 16/86 (18.6%) MS patients, 4/41 (9.8%) NMOSD patients and 1/31 (3.2%) healthy controls had increased SIGLEC1 levels. The gene discussed is SIGLEC1; the disease is myeloid sarcoma.